TIL + pembro regimen achieves 24% response rate in solid epithelial tumors, marking a step forward in immunotherapy research

The Directors: Yolanda Sanchez and Kelvin Lee talk about making cancer centers more resilient
“Diverse ecosystems are more robust than non-diverse ecosystems. That is a biological fact.”

“We’ve always argued that money comes and goes, but if you lose a generation of scientists—you can’t buy them back,” said Kelvin Lee, director of the Indiana University Simon Comprehensive Cancer Center.

February 27, 2026

Vol.52 No.08

By Claire Marie Porter and Paul Goldberg

Clinical Roundup

Rybrevant Faspro + immunotherapy shows strong clinical benefit for recurrent or metastatic head-and-neck cancer

Data from the phase Ib/II OrigAMI-4 study found that first-line treatment with investigational subcutaneous amivantamab and hyaluronidase-lpuj in combination with a PD-1 inhibitor delivered clinically meaningful and durable antitumor activity in patients with head and neck squamous cell carcinoma that is recurrent or metastatic, PD-L1-positive, and HPV-unrelated.

February 27, 2026

Vol.52 No.08

Clinical Roundup

Adjuvant immunotherapy + hormone therapy may counteract immune-suppression in early-stage prostate cancer, Mayo-led study finds

Pairing a next-generation immunotherapy with standard hormone therapy before surgery may help overcome a long-standing barrier in early-stage prostate cancer treatment, according to a Mayo Clinic-led study.

February 27, 2026

Vol.52 No.08

News Analysis

NIH Director Bhattacharya named acting CDC director in latest public health shakeup
The temporary appointment concentrates vast authority in the hands of one person

NIH Director Jay Bhattacharya has taken a second big job.

February 20, 2026

Vol.52 No.07

By Claire Marie Porter

In Brief

WVU Cancer Institute first in the world to treat ultra-rare leukemia using novel subcutaneous immunotherapy

A WVU Cancer Institute team has achieved a global medical first in a clinical trial examining the efficacy of subcutaneous blinatumomab (Blincyto) in treating one of the rarest and most aggressive forms of leukemia.

February 20, 2026

Vol.52 No.07

Capitol Hill

After a brief government shutdown, FY26 funding bill is signed into law
NIH gets $415M raise, NCI gets $128M more, CDMRP funding largely restored

On Feb. 3, the House of Representatives passed the Senate Amendment to H.R. 7148, the Consolidated Appropriations Act, 2026, by a vote of 217 to 214. Later that day, President Donald Trump signed the bill into law, officially ending the brief partial government shutdown that began on Jan. 31.

February 06, 2026

Vol.52 No.05

By Jacquelyn Cobb

TIL + pembro regimen achieves 24% response rate in solid epithelial tumors, marking a step forward in immunotherapy research

YOU MAY BE INTERESTED IN

The Directors: Yolanda Sanchez and Kelvin Lee talk about making cancer centers more resilient
“Diverse ecosystems are more robust than non-diverse ecosystems. That is a biological fact.”

Rybrevant Faspro + immunotherapy shows strong clinical benefit for recurrent or metastatic head-and-neck cancer

Adjuvant immunotherapy + hormone therapy may counteract immune-suppression in early-stage prostate cancer, Mayo-led study finds

NIH Director Bhattacharya named acting CDC director in latest public health shakeup
The temporary appointment concentrates vast authority in the hands of one person

WVU Cancer Institute first in the world to treat ultra-rare leukemia using novel subcutaneous immunotherapy

After a brief government shutdown, FY26 funding bill is signed into law
NIH gets $415M raise, NCI gets $128M more, CDMRP funding largely restored

Renew today!

Subscriber content

Never miss an issue!

Login

TIL + pembro regimen achieves 24% response rate in solid epithelial tumors, marking a step forward in immunotherapy research

YOU MAY BE INTERESTED IN

The Directors: Yolanda Sanchez and Kelvin Lee talk about making cancer centers more resilient“Diverse ecosystems are more robust than non-diverse ecosystems. That is a biological fact.”

Rybrevant Faspro + immunotherapy shows strong clinical benefit for recurrent or metastatic head-and-neck cancer

Adjuvant immunotherapy + hormone therapy may counteract immune-suppression in early-stage prostate cancer, Mayo-led study finds

NIH Director Bhattacharya named acting CDC director in latest public health shakeupThe temporary appointment concentrates vast authority in the hands of one person

WVU Cancer Institute first in the world to treat ultra-rare leukemia using novel subcutaneous immunotherapy

After a brief government shutdown, FY26 funding bill is signed into lawNIH gets $415M raise, NCI gets $128M more, CDMRP funding largely restored

Never miss an issue!

Login

The Directors: Yolanda Sanchez and Kelvin Lee talk about making cancer centers more resilient
“Diverse ecosystems are more robust than non-diverse ecosystems. That is a biological fact.”

NIH Director Bhattacharya named acting CDC director in latest public health shakeup
The temporary appointment concentrates vast authority in the hands of one person

After a brief government shutdown, FY26 funding bill is signed into law
NIH gets $415M raise, NCI gets $128M more, CDMRP funding largely restored